Clin2
NCT06217666Possibly a fitNot yet recruiting

Radiation and immunotherapy for advanced pancreatic cancer

Pancreatic Adenocarcinoma

Part of Cancer, Digestive system, Hormones & metabolism clinical trials.

This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
24 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a type of pancreatic cancer called adenocarcinoma confirmed by biopsy.
  • Your tumor is considered either locally advanced (has not spread to other organs) or cannot be removed with surgery, or your doctor has decided not to do surgery for other reasons.
  • You have finished at least one round of chemotherapy without your cancer getting worse or spreading to other parts of your body.
  • Your tumor is clearly visible on a CT scan and is in a position where doctors can safely give targeted radiation (SBRT) and then inject an experimental immunotherapy drug (PCX12) directly into the tumor using a thin tube (endoscope).
  • You are generally healthy enough to handle these procedures (ECOG score 0–2, meaning you can be up and about, even if you need some help).
  • If you could become pregnant or father a child, you agree to use effective birth control during the study and for at least 3 months after the final treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07126158Recruiting· Phase 2
Radiation plus targeted drugs for advanced pancreatic cancer

This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.

St Louis, Missouri
NCT06026943Recruiting
Alpha radiation therapy for locally advanced pancreatic cancer

This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.

Verona
NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety

This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.

Holon
NCT06453486Recruiting· Phase 2
High dose radiation for pancreatic cancer after chemo

This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.

Toronto, Ontario
NCT06691425Recruiting
Radiation for pancreatic cancer that can't be removed

This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.

Edegem, Antwerpen
NCT07600268Recruiting· Phase 2
Radiation plus maintenance drugs for advanced pancreatic cancer

This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.

Jinan, Shandong

Hear when a new Pancreatic Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.